Fighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck, and lung cancers (Immune Checkpoint Response Enabling Adenovirus Technology )

Projektinformationen

I-CREATE

ID Finanzhilfevereinbarung: 190121193

DOI 10.3030/190121193

Projekt abgeschlossen

EK-Unterschriftsdatum 11 November 2022

Startdatum 1 Juli 2022

Enddatum 31 Dezember 2023

Finanziert unter

• The European Innovation Council (EIC)

Gesamtkosten € 5 073 000,00

EU-Beitrag € 2 100 000,00

Koordiniert durch

TILT BIOTHERAPEUTICS OY
Finland

Leistungen

Documents, reports (1)

Interim clinical data from at least 3 patients

Deliverable relates to reporting of interim results of the ongoing clinical studies T115 T215

Websites, patent fillings, videos etc. (2)

First-patients treated

Update on the trial progress in the first study sites in Docrates finland and Mayo Clinic Minnesota

IND/clinical trial approved (T776)

IND approved for T776 headneck cancer clinical trial